Nara Dashdorj (@naradashdorj) 's Twitter Profile
Nara Dashdorj

@naradashdorj

Onom Foundation

ID: 2502703683

linkhttp://eleg.mn/ calendar_today22-04-2014 22:29:22

6,6K Tweet

2,2K Takipçi

2,2K Takip Edilen

CGH (@aga_cgh) 's Twitter Profile Photo

Among patients with HBV-related #HCC, those treated with tenofovir had a better prognosis than those treated with entecavir, particularly among those with prolonged survival: ow.ly/q5oI50UTFkQ

Among patients with HBV-related #HCC, those treated with tenofovir had a better prognosis than those treated with entecavir, particularly among those with prolonged survival: ow.ly/q5oI50UTFkQ
Arndt Vogel (@arndtvogel) 's Twitter Profile Photo

🔥off the press: Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Annals of Oncology doi.org/10.1016/j.anno… 👉get the lastest update on HCC management 👉Multiple options > MDT is key ESMO - Eur. Oncology EASL Education ILCA #livertwitter

🔥off the press:
Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
<a href="/Annals_Oncology/">Annals of Oncology</a> 
doi.org/10.1016/j.anno…
👉get the lastest update on HCC management
👉Multiple options &gt; MDT is key
<a href="/myESMO/">ESMO - Eur. Oncology</a> <a href="/EASLedu/">EASL Education</a> <a href="/ILCAnews/">ILCA</a> #livertwitter
Dr. Nina Niu Sanford (@niusanford) 's Twitter Profile Photo

Dr. Josep Llovet is the #1 cited HCC researcher in the world...lead of SHARP, LEAP-012 trials (any many more), & heads BCLC. Here we chat about: -trial endpoints -his thoughts on SBRT -career advice Link to full 17 min video on YouTube in replies.

Ludwig Cancer (@ludwig_cancer) 's Twitter Profile Photo

Princeton University Ludwig Princeton University Associate Director Eileen P. White, PhD discusses the importance of the clinical component connection of Ludwig’s mission to advance the prevention and control of cancer. #CancerResearch youtu.be/L5xLxO7qAAI

Lillian Siu (@lillian_siu) 's Twitter Profile Photo

It's pleasure coauthoring this Cancer Cell commentary with 2 talented drug development fellows #gregoire marret and #mercedes herrera Princess Margaret Cancer Centre - "Turning the Kaleidoscope: Innovations shaping the future of clinical trials design" authors.elsevier.com/a/1kljp5TA51lC…

It's pleasure coauthoring this <a href="/Cancer_Cell/">Cancer Cell</a> commentary with 2 talented drug development fellows #gregoire marret and #mercedes herrera <a href="/pmcancercentre/">Princess Margaret Cancer Centre</a> - "Turning the Kaleidoscope: Innovations shaping the future of clinical trials design"
authors.elsevier.com/a/1kljp5TA51lC…
Eric Topol (@erictopol) 's Twitter Profile Photo

Of >105,000 participants with 30-year follow-up, only 9.3% achieved healthy aging (age 70, w/o any chronic diseases). Their diet was significantly associated with this outcome🧵 Nature Medicine

Of &gt;105,000 participants with 30-year follow-up, only 9.3% achieved healthy aging (age 70, w/o any chronic diseases). Their diet was significantly associated with this outcome🧵 <a href="/NatureMedicine/">Nature Medicine</a>
Martin Picard (@mitopsychobio) 's Twitter Profile Photo

The brain is full of mitochondria! But how many, and where? Different types of mitochondria specialize for energy transformation and other functions In MitoBrainMap v1.0 we provide the first maps of mitochondrial content and OxPhos capacity across the human brain

Martin Picard (@mitopsychobio) 's Twitter Profile Photo

Brain mitochondria are gorgeous! 🥹 Beautiful MitoBrainMap v1.0 collaboration with neuroanatomist, neuropsychologist, and white matter expert Michel Thiebaut de S

Brain mitochondria are gorgeous! 🥹

Beautiful MitoBrainMap v1.0 collaboration with neuroanatomist, neuropsychologist, and white matter expert <a href="/MichelTdS/">Michel Thiebaut de S</a>
nature (@nature) 's Twitter Profile Photo

Biologists have built one of the most detailed pictures of pregnancy's true toll on the body. Read the full story: go.nature.com/4hUpNES

Biologists have built one of the most detailed pictures of pregnancy's true toll on the body.

Read the full story: go.nature.com/4hUpNES
Neil Stone (@drneilstone) 's Twitter Profile Photo

The HPV vaccine is CRUSHING cervical cancer and at this rate will eliminate it!! An anti cancer vaccine. It's a medical miracle. HHS Secretary RFK Jr is against it

The HPV vaccine is CRUSHING cervical cancer and at this rate will eliminate it!!

An anti cancer vaccine. It's a medical miracle.

HHS Secretary RFK Jr is against it
ESMO - Eur. Oncology (@myesmo) 's Twitter Profile Photo

📣 ESMO Living Guideline on Hepatocellular Carcinoma: 👉 New title with the latest recommendations and algorithms in an interactive format. #ClinicalPracticeGuideline Arndt Vogel 🔗 ow.ly/CHpJ50VHbYg

📣 ESMO Living Guideline on Hepatocellular Carcinoma:
👉 New title with the latest recommendations and algorithms in an interactive format.
#ClinicalPracticeGuideline <a href="/ArndtVogel/">Arndt Vogel</a>
🔗 ow.ly/CHpJ50VHbYg
Хуульч Батхүү (@batkhuu_lw) 's Twitter Profile Photo

Өдөржингөө НӨАТ гэж бичлээ. Сангийн яам, Татварынхан дараах асуултанд хариу өгнө үү? 1) Одоо хүчин төгөлдөр үйлчилж байгаа хуулийн 13-р зүйлд боловсрол, эрүүл мэнд, оршуулгын үйлчилгээ НӨАТ-с чөлөөлөгдөнө гэж байгаа. Гэтэл энэ заалт хасагджээ. Хуулиараа чөлөөлөгдөх жагсаалтанд

NEJM (@nejm) 's Twitter Profile Photo

Presented at #ASCO25: A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results:

Presented at #ASCO25: 

A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results:
Bishal Gyawali, MD, PhD, FASCO (@oncology_bg) 's Twitter Profile Photo

The most practice changing trial from #ASCO25 is now live on NEJM .If this was a drug, this would be approved today. Globally relevant and low-cost intervention that is not only delaying relapse but actually improving survival. Perfect case example of a #cancergroundshot trial.

The most practice changing trial from #ASCO25 is now live on <a href="/NEJM/">NEJM</a> .If this was a drug, this would be approved today. Globally relevant and low-cost intervention that is not only delaying relapse but actually improving survival. 
Perfect case example of a #cancergroundshot trial.
Nicolas Hart (@drnicolashart) 's Twitter Profile Photo

A standing ovation for #CHALLENGE trial at #ASCO25 - first in world to definitively show exercise reduces recurrence and improves survival: “For every 16 people, exercise prevents 1 person from recurrent/new cancer” “For every 14 people, exercise prevents 1 person from dying”

A standing ovation for #CHALLENGE trial at #ASCO25 - first in world to definitively show exercise reduces recurrence and improves survival:

“For every 16 people, exercise prevents 1 person from recurrent/new cancer”

“For every 14 people, exercise prevents 1 person from dying”
Stephen V Liu, MD (@stephenvliu) 's Twitter Profile Photo

This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.

This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.
Arndt Vogel (@arndtvogel) 's Twitter Profile Photo

Long-term outcomes and OS for zanidatamab + CTx in HER2+ mGEA: 4-year follow-up #ASCO25 🔎Phs-2 👉ORR 76 %m DoR 18.7 mo 👉mPFS 12.5 mo 👉mOS 36 mo 👉Manageable safety 👉95% concordance btw ctDNA & IHC 🧐 strong efficacy signal, phase-3 data awaited ESMO - Eur. Oncology

Long-term outcomes and OS for zanidatamab + CTx in HER2+ mGEA: 4-year follow-up
#ASCO25
🔎Phs-2
👉ORR 76 %m DoR 18.7 mo
👉mPFS 12.5 mo
👉mOS 36 mo
👉Manageable safety
👉95% concordance btw ctDNA &amp; IHC
🧐 strong efficacy signal, phase-3 data awaited
<a href="/myESMO/">ESMO - Eur. Oncology</a>